Phase I Study Protocol: NKTR-255 as Monotherapy or Combined with Daratumumab or Rituximab in Hematologic MalignanciesNina Shah, Krina K. Patel, Miguel‐Angel Perales et al.|Future Oncology|2021Cited by 21
Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8 + T-Cells: Preliminary Results from a Phase 1 StudyCameron J. Turtle, Nina Shah, Neha Dixit et al.|Blood|2021Cited by 6
Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic MalignanciesNina Shah, Krina K. Patel, Alan Tan et al.|Blood|2021Cited by 4
NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)Sairah Ahmed, Joseph P. McGuirk, John F. DiPersio et al.|Blood|2024Cited by 3
NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)Sairah Ahmed, Joseph P. McGuirk, John F. DiPersio et al.|Transplantation and Cellular Therapy|2025Cited by 3